title: Late-onset endothelin-A receptor blockade reduces podocyte injury in homozygous Ren-2 rats despite severe hypertension.
abstract: We have recently found in male homozygous hypertensive Ren-2 transgenic rats (TGRs) fed a high-salt diet that early onset selective endothelin (ET) A (ET(A)) or nonselective ET(A)/ET B (ET(B)) receptor blockade improved survival rate and reduced proteinuria, glomerulosclerosis, and cardiac hypertrophy, whereas selective ET(A) receptor blockade also significantly attenuated the rise in blood pressure. Because antihypertensive therapy in general is known to be more efficient when started at early age, our study was performed to determine whether onset of ET receptor blockade at a later age in animals with established hypertension will have similar protective effects as does early-onset therapy. Male homozygous TGRs and age-matched normotensive Hannover Sprague-Dawley rats were fed a high-salt diet between days 51 and 90 of age. TGRs received vehicle (untreated), the selective ET(A) receptor blocker atrasentan (ABT-627), or the nonselective ET(A)/ET(B) receptor blocker bosentan. Survival rates in untreated and bosentan-treated TGRs were 50% and 64%, respectively, whereas with atrasentan, survival rate of TGR was 96%, thus, similar to 93% in Hannover Sprague-Dawley rats. From day 60 on, systolic blood pressure in atrasentan-treated TGRs was transiently lower (P<0.05) than in untreated or bosentan-treated TGRs. Glomerular podocyte injury was substantially reduced with atrasentan treatment independent of severe hypertension and strongly correlated with survival (P<0.001). Our data indicate that in homozygous TGR ET receptors play an important role also in established hypertension. Selective ET(A) receptor blockade not only reduces podocyte injury and end-organ damage but also improves growth and survival independently of hypertension.
authors.affiliation: Center for Experimental Medicine, Institute for Clinical and Experimental Medicine, Videnska 1958/9, CZ-140 21, Prague 4, Czech Republic.
authors.forename: Martin
authors.initials: M
authors.lastname: Opocenský
authors.forename: Herbert J
authors.initials: HJ
authors.lastname: Kramer
authors.forename: Angela
authors.initials: A
authors.lastname: Bäcker
authors.forename: Zdenka
authors.initials: Z
authors.lastname: Vernerová
authors.forename: Václav
authors.initials: V
authors.lastname: Eis
authors.forename: Ludek
authors.initials: L
authors.lastname: Cervenka
authors.forename: Vera
authors.initials: V
authors.lastname: Certíková Chábová
authors.forename: Vladimír
authors.initials: V
authors.lastname: Tesar
authors.forename: Ivana
authors.initials: I
authors.lastname: Vanecková
mesh_terms: D000818:Animals; D030801:Animals, Genetically Modified; D065130:Endothelin A Receptor Antagonists; D065131:Endothelin B Receptor Antagonists; D006973:Hypertension / Q000235:genetics* / Q000401:mortality / Q000503:physiopathology / Q000517:prevention & control*; D008297:Male; D051379:Mice; D050199:Podocytes / Q000378:metabolism / Q000473:pathology*; D051381:Rats; D011922:Rats, Mutant Strains; D017207:Rats, Sprague-Dawley; D044022:Receptor, Endothelin A / Q000502:physiology; D044023:Receptor, Endothelin B / Q000502:physiology; D015996:Survival Rate; D013599:Systole / Q000235:genetics
chemical_list: D065130:Endothelin A Receptor Antagonists; D065131:Endothelin B Receptor Antagonists; D044022:Receptor, Endothelin A; D044023:Receptor, Endothelin B